184 related articles for article (PubMed ID: 36724301)
1. Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study.
Chico A; Navas de Solís S; Lainez M; Rius F; Cuesta M
Diabetes Technol Ther; 2023 Apr; 25(4):242-249. PubMed ID: 36724301
[No Abstract] [Full Text] [Related]
2. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up.
Amadou C; Franc S; Benhamou PY; Lablanche S; Huneker E; Charpentier G; Penfornis A;
Diabetes Care; 2021 Mar; 44(3):844-846. PubMed ID: 33431420
[TBL] [Abstract][Full Text] [Related]
3. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
[TBL] [Abstract][Full Text] [Related]
4. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G
Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978
[TBL] [Abstract][Full Text] [Related]
5. Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial - study protocol.
Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C; Benhalima K
BMC Pregnancy Childbirth; 2023 Mar; 23(1):180. PubMed ID: 36927458
[TBL] [Abstract][Full Text] [Related]
6. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
7. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
[TBL] [Abstract][Full Text] [Related]
8. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
[No Abstract] [Full Text] [Related]
9. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
10. No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial.
Franc S; Benhamou PY; Borot S; Chaillous L; Delemer B; Doron M; Guerci B; Hanaire H; Huneker E; Jeandidier N; Amadou C; Renard E; Reznik Y; Schaepelynck P; Simon C; Thivolet C; Thomas C; Hannaert P; Charpentier G
Diabetes Obes Metab; 2021 Sep; 23(9):2170-2176. PubMed ID: 34009725
[TBL] [Abstract][Full Text] [Related]
11. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
[No Abstract] [Full Text] [Related]
12. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
[No Abstract] [Full Text] [Related]
13. Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life setting.
Oriot P; Hermans MP
J Diabetes Complications; 2023 Feb; 37(2):108385. PubMed ID: 36603333
[TBL] [Abstract][Full Text] [Related]
14. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
[TBL] [Abstract][Full Text] [Related]
15. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study.
Lachal S; Tourki Y; Franc S; Huneker E; Charpentier G; Benhamou PY
J Diabetes Sci Technol; 2023 Jan; 17(1):176-185. PubMed ID: 34658265
[TBL] [Abstract][Full Text] [Related]
17. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment.
Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V
Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group.
Landau Z; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Haim A; Nir J; Rachmiel M; Pinhas-Hamiel O
Endocrine; 2024 Jun; 84(3):943-950. PubMed ID: 38225516
[TBL] [Abstract][Full Text] [Related]
19. First Generation of a Modular Interoperable Closed-Loop System for Automated Insulin Delivery in Patients With Type 1 Diabetes: Lessons From Trials and Real-Life Data.
Benhamou PY; Adenis A; Lablanche S; Franc S; Amadou C; Penfornis A; Kariyawasam D; Beltrand J; Charpentier G
J Diabetes Sci Technol; 2023 Nov; 17(6):1433-1439. PubMed ID: 37449762
[TBL] [Abstract][Full Text] [Related]
20. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
Front Public Health; 2022; 10():990281. PubMed ID: 36091534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
